25
Views
4
CrossRef citations to date
0
Altmetric
Research Article

Role of NAD(P)H:quinone oxidoreductase polymorphism at codon 187 in susceptibility to lung, laryngeal and oral/pharyngeal cancers

, , , , &
Pages 440-447 | Published online: 29 Sep 2008

  • BOUCHARDY, C., WIKMAN, H., BENHAMOC, S., HIRVONEN, A., DAYER, P. and HUSGAFVEL-PCJRSIAINEN, K. 1997, CYP1A1 genetic polymorphisms, tobacco smoking and lung cancer risk in a French Caucasian population. Biomarkers, 2, 131-134.
  • BRESLOW, N. E. and DAY, N. E. 1980, The Analysa of Case-Control Studies. Statistical Methods in Cancer Research, Vol. 1, Scientific Publications No 32 (Lyon: International Agency for Research on Cancer).
  • CHEN, H., LUM, A., SEIFRIED, A., WILKENS, L. R. and LE MARCHAND, L. 1999, Association of the NAD(P)H:quinone oxidoreductase 609C->T polymorphism with decreased lung cancer risk. Cancer Research, 59, 3045-3048.
  • GAEDIGK, A., TYNDALE, R. F., JURIMA-ROMET, M., SELLERS, E. M., GRANT, D. M. and LEEDER, J. S. 1998. NAD(P)H:quinone oxidoreductase polymorphisms and allele frequencies in Caucasian, Chinese and Canadian native Indian and Inuit populations. Pharmacogenetics, 8, 305-313.
  • JOSEPH, P. and JAISWAL, A. K. 1994, NAD(P)H:quinone oxidoreductase 1 (DT-diaphorase) specifically prevents the formation of benzo[a]pyrene quinone-DNA adducts generated by cytochrome P4501A1 and P450 reductase. Proceeding of the National Academy of Sciences of the USA, 91, 8413-8417.
  • JOURENKOVA, N., REINIKANEN, M., BOUCHARDY, C., HUSGAFVEL-PURSIAINEN, K., DAYER, P., BENHAMOU, S. and HIRVONEN, A. 1997, Effects of glutathione S-transferase GSTM1 and GSTT1 genotypes on lung cancer risk among smokers. Pharmacogenetics, 7, 515-518.
  • JOURENKOVA-MlRONOVA, N., VOHO, A., BOUCHARDY, C., WlKMAN, H., DAYER, P., BENHAMOU, S. and HIRVONEN, A. 1999, Glutathione S-transferase GSTM1, GSTM3, GSTP1 and GSTT1 genotypes and the risk of smoking-related oral and pharyngeal cancers. International Journal of Cancer, 81, 44-48.
  • KELSEY, K. T., Ross, D., TRAVER, R. D., ZUO, Z.-F., SPITX, M. R., WANG, M., Xu, X., LEE, B.-K., SCHWARTZ, B. S. and WIENCKE, J. K. 1997, Ethnic variation in the prevalence of a common NAD(P)H:quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. British Journal of Cancer, 76, 852-854.
  • LIN, P., WANG, H. J., LEE, H., LEE, H. S., WANG, S. L., HSUEH, Y. M., TSAI, K. J. and CHE, C.Y. 1999, NAD(P)H:quinone oxidoreductase polymorphism and lung cancer in Taiwan. Journal of Toxicology and Environmental Health, 58, 187-197.
  • PÉQUIGNOT, G., CROSIGNANI, P., TERRACINI, B., ASCUNCE, N., ZUBIRI, A., RAYMOND, L., ESTÉVE, J. and TUYNS, A. J. 1988, A comparative study of smoking, drinking, and dietary habits in population samples in France, Italy, Spain, and Switzerland. III. Consumption of alcohol. Revue d'Epidemiologie et de Sante Publique, 36, 177-185.
  • ROSWOLD, E. A., McGLYNN, K. A., LUSTBADER, E. D. and BUETOW, K. H. 1995, Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics, 5, 199-206.
  • SIEGEL, D., McGUINNESS, S. M., WINSKI, S. L. and Ross, D. 1999, Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics, 9, 113121.
  • TALALAY, P., FAHEY, J. W., HOLTZCLAW, W. D., PRESTERA, T. and ZHANG, Y. 1995, Chemoprotection against cancer by phase 2 enzyme induction. Toxicology Letters, 82-83, 173-179.
  • TRAVER, R. D., HORIKOSHI, T., DANENBERG, K. D., STADLBAUER, T. H. W., DANENBERG, P. V., Ross, D. and GIBSON, N. W. 1992, NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Research, 52, 797-802.
  • TRAVER, R. D., SIEGEL, D., BEALL, H. D., GIBSON, N. W., FRANKLIN, W. A. and Ross, D. 1997, Characterization of a polymorphism in NAD(P)H:quinone oxidoreductase (DT-diaphorase). British Journal of Cancer, 75, 69-75.
  • VINETS, P., D'ERRICO, A., MALATS, N. and BOETTA, P. 1999, Overall evaluation and research perspectives. In Metabolic Polymorphisms and Susceptibility to Cancer, edited by P. Vineis, N. Malats, M. Lang, A. d'Errico, N. Caporaso, J. Cuzick and P. Boffetta (Lyon: International Agency for Research on Cancer), pp. 403-408.
  • WIENCKE, J. K., SPITZ, M. R., McMILLAN, A. and KELSEY, K. T. 1997, Lung cancer in MexicanAmericans and African-Americans is associated with the wild-type genotype of the NAD(P)H:quinone oxidoreductase polymorphism. Cancer Epidemiology, Biomarkers and Prevention, 6, 87-92.
  • WORKMAN, P. 1994, Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase. Oncology Research, 6, 461-475.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.